Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-020572 in Healthy Volunteers and Chronic Hepatitis B
NCT05001022Phase 1Terminated
- Sponsor
- Aligos Therapeutics
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ALG-020572 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 120 days. Started Sep 2021; status: terminated.
02
Drugs
ALG-020572
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05001022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001022.